Narayana Hrudayalaya's Q1 FY27 Revenue Hits ₹2683 Crore, Profit Jumps 40%
Narayana Hrudayalaya's revenue surged 78% to ₹2683.6 crore in Q1 FY27, with profits soaring by 40% amid robust performance across regions.
Bengaluru-based hospital chain Narayana Hrudayalaya Limited has reported a substantial increase in its financial performance for the first quarter of fiscal year 2027, ending in June. The company saw a 78% year-on-year rise in consolidated revenue, reaching ₹2683.6 crore. This impressive growth was accompanied by a 40% year-on-year increase in consolidated EBITDA, which stood at ₹505.2 crore, despite a decrease in EBITDA margin from 23.9% to 18.8%.
Profit Surge and Regional Performance
Profit after tax for the quarter reached ₹207.3 crore, representing a 5.7% rise from ₹196.1 crore in the same period last year. Narayana Hrudayalaya's operations in India reported a 17% year-on-year increase in revenue to ₹1324.7 crore. The company’s Cayman Islands operations contributed ₹551.4 crore, while its UK operations added ₹825.7 crore to the quarterly revenue.
Strategies Driving Growth
Dr. Emmanuel Rupert, Managing Director and Group CEO of Narayana Hrudayalaya, highlighted that the growth was driven by increased patient footfall and a focus on high-end and complex procedures. The company has been expanding its Integrated Care ecosystem, which includes clinics and insurance services, to enhance patient outreach and strengthen its hospital network.
The Cayman business performed well, supported by the One Health insurance platform, which has improved patient access and affordability. Meanwhile, the UK business, which Narayana Hrudayalaya recently acquired, remains stable as integration efforts advance, moving closer to full separation from its previous parent company.
Outlook and Future Plans
The first quarter's performance sets a strong foundation for the rest of the fiscal year, with expectations of continued growth across all regions. The company's strategic focus on expanding its service offerings and enhancing patient access is expected to maintain momentum and drive future profitability.